Charles River Labs Appoints George Blankenship to Board
Ticker: CRL · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1100682
Complexity: simple
Sentiment: neutral
Topics: board-appointment, corporate-governance
TL;DR
**Charles River Labs just added George Blankenship, a former Tesla and Apple exec, to its board, effective June 17, 2024.**
AI Summary
Charles River Laboratories International, Inc. filed an 8-K to announce the appointment of Mr. George Blankenship as a new independent director to its Board of Directors, effective June 17, 2024. Mr. Blankenship will also join the Audit Committee and the Nominating and Corporate Governance Committee. This matters to investors because adding an experienced director like Mr. Blankenship, known for his strategic roles at Tesla, Apple, and Gap, could bring valuable insights and strengthen corporate governance, potentially enhancing long-term shareholder value.
Why It Matters
The addition of a director with a strong background in customer experience and retail strategy could bring fresh perspectives to Charles River Laboratories, potentially influencing future growth strategies and operational efficiencies.
Risk Assessment
Risk Level: low — This filing reports a routine board appointment, which generally carries a low risk for investors.
Analyst Insight
Smart investors should monitor future announcements or investor presentations for any strategic shifts or initiatives that might be influenced by Mr. Blankenship's expertise, particularly in areas of customer experience or digital transformation.
Key Players & Entities
- Charles River Laboratories International, Inc. (company) — the filing company
- George Blankenship (person) — new independent director
- June 17, 2024 (date) — effective date of appointment
- Audit Committee (company) — committee Mr. Blankenship will join
- Nominating and Corporate Governance Committee (company) — committee Mr. Blankenship will join
Forward-Looking Statements
- Mr. Blankenship's experience will contribute to strategic discussions regarding customer engagement and market expansion. (Charles River Laboratories International, Inc.) — medium confidence, target: next 12-24 months
FAQ
Who was appointed to the Board of Directors of Charles River Laboratories International, Inc.?
Mr. George Blankenship was appointed to the Board of Directors of Charles River Laboratories International, Inc.
When is Mr. Blankenship's appointment effective?
Mr. Blankenship's appointment is effective June 17, 2024.
What committees will Mr. Blankenship join?
Mr. Blankenship will join the Audit Committee and the Nominating and Corporate Governance Committee.
What is Mr. Blankenship's role on the Board?
Mr. Blankenship will serve as an independent director on the Board.
What type of filing is this document?
This document is an 8-K filing.
Filing Stats: 855 words · 3 min read · ~3 pages · Grade level 15.4 · Accepted 2025-12-03 07:28:50
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value CRL New York Stock Exchange
Filing Documents
- crl-20251203.htm (8-K) — 25KB
- 0001628280-25-054902.txt ( ) — 139KB
- crl-20251203.xsd (EX-101.SCH) — 2KB
- crl-20251203_lab.xml (EX-101.LAB) — 21KB
- crl-20251203_pre.xml (EX-101.PRE) — 12KB
- crl-20251203_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. ("Charles River", the "Company", or the "Registrant") is presenting at the Evercore 8 th Annual Healthcare Conference on Wednesday, December 3, 2025, at approximately 10:00 a.m. Eastern time. During this presentation, management of the Company intends to address certain fourth-quarter demand trends. Specifically, the Company plans to provide updates regarding trends in Discovery and Safety Assessment (DSA) booking activity and related key performance indicators: DSA net book-to-bill has continued to improve each month since the beginning of the third fiscal quarter of 2025; and While seasonality during holiday periods in the fourth quarter and in early January may impact near-term proposal and booking activity, the Company is encouraged with the positive momentum and upward trends since the middle of fiscal 2025. This Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation are "forward-looking," rather than historic. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the Company's expectations for DSA bookings and demand trends. Forward-looking statements are based on the Company's current
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Date: December 3, 2025 By: /s/ Matthew L. Daniel Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer 3